Endothelial cell (EC) identity is in part genetically predetermined. Transcription factor NR2F2 (also known as chicken ovalbumin upstream promoter transcription factor II, COUP-TFII) plays a key role in EC fate decision making; however, many of the underlying mechanisms remain enigmatic. In the present study, we demonstrate that NR2F2 differentially regulates gene expression of venous versus lymphatic ECs (LECs) and document a novel paradigm whereby NR2F2 homodimers induce a venous EC fate, while heterodimers with the LEC-specific transcription factor PROX1 instruct LEC lineage specification. NR2F2 homodimers inhibit arterial differentiation in venous ECs through direct binding to the promoter regions of the Notch target genes HEY1 and HEY2 (HEY1/2), whereas NR2F2/PROX1 heterodimers lack this inhibitory effect, resulting at least in part in non-canonical HEY1/2 expression in LECs. Furthermore, NR2F2/PROX1 heterodimers actively induce or are permissive for the expression of a major subset of LEC-specific genes. In addition to NR2F2/PROX1 heterodimerisation, the expression of HEY1 and some of these LEC-specific genes is dependent on PROX1 DNA binding. Thus, NR2F2 homodimers in venous ECs and NR2F2/PROX1 heterodimers in LECs differentially regulate EC subtype-specific genes and pathways, most prominently the Notch target genes HEY1/2. This novel mechanistic insight could pave the way for new therapeutic interventions for vascular-bed-specific disorders.
Introduction
ECs lining the inside of veins, arteries and lymphatic vessels feature remarkable functional, molecular and morphological heterogeneity. While these characteristics are partly acquired by exposure to environmental cues, genetic studies support the concept that EC identity is also intrinsically predetermined (Aird, 2007a; Aird, 2007b) . Arterial ECs (AECs) express EphrinB2, while its receptor EphB4 is present on their venous counterparts (VECs), a polarity that is established before the onset of blood flow (Wang et al., 1998) . Similarly, LECs uniquely express the transcription factor Prox1, before the lymphatic system becomes functional (Srinivasan et al., 2007) . Many other molecular players participate in EC fate decisions, including Notch, sonic hedgehog (Shh), vascular endothelial growth factor (VEGF), angiopoietins, transforming growth factor-b, Wnt, Sry-related HMG box (Sox), forkhead box (Fox)C1/2, adrenomedullin, Spreds and phosphatidylinositol-3 kinase (Corada et al., 2010; Oliver and Srinivasan, 2010; Swift and Weinstein, 2009 ). Often they are organised hierarchically, such as the Shh-VEGF-Notch cascade establishing an arterial phenotype.
The formidable challenge of unravelling the molecular complexity of AEC, VEC and LEC differentiation is further enhanced by the notion that several factors are commonly expressed amongst EC subtypes. Notch receptors and EphrinB2, thought to be restricted to AECs, were later found on LECs (Geudens et al., 2010; Kang et al., 2010; Shawber and Kitajewski, 2008) . Since LECs originate by transdifferentiation from VECs, it is not surprising that they also share some molecules (Srinivasan et al., 2007; Srinivasan et al., 2010) . One of these is the transcription factor COUP-TFII, which we will refer to as 'NR2F2'. It belongs to a family of nuclear orphan receptors that play key roles in neuronal development, organogenesis, cell fate determination and metabolic homeostasis (Li et al., 2009; Tsai and Tsai, 1997) . Targeted NR2F2 deletion in mice revealed its critical role in cardiovascular development (Pereira et al., 1999) . Furthermore, EC-specific deletion demonstrated a cellautonomous function of NR2F2 in establishing VEC identity during development (You et al., 2005) . Recently, NR2F2 was shown to be required for induction of Prox1 -a master-switch for LEC differentiation -and thus for LEC transdifferentiation from VECs (Srinivasan et al., 2007; Srinivasan et al., 2010) .
An intriguing question is how a transcription factor, commonly expressed by distinct EC subtypes, can regulate distinct EC fates and which pathways lay downstream of NR2F2 in the two EC subtypes. Based on the observation that NR2F2-deficient VECs featured ectopic expression of neuropilin (Nrp)1 -a VEGF co-receptor -in addition to Notch1 and its downstream target Hey1 in mice, it was proposed that NR2F2 imposes a VEC phenotype by blocking activation of the arterial VEGF-Notch cascade (You et al., 2005) . Another model suggested that NR2F2 cooperates with PROX1 in LECs to interrupt the VEGF-Notch pathway to prevent AEC specification and induce a LEC fate (Kang et al., 2010) . However, some important mechanistic riddles remain unresolved. While both models agree on NR2F2's inhibitory role on the arterialising VEGFNotch pathway, the underlying mechanisms of Notch inhibition are not fully established in VECs and LECs (Kang et al., 2010; Srinivasan et al., 2010; Swift and Weinstein, 2009) . While the expression of Notch pathway members was documented in LECs (Kang et al., 2010; Shawber et al., 2007; Shawber and Kitajewski, 2008; Zheng et al., 2011) , it remains unclear which mechanisms drive this expression and whether or how they play a role in LEC specification, maintenance and function. Conflicting results have been reported, some suggesting a positive role for Notch signalling in lymphangiogenesis during zebrafish development (Geudens et al., 2010) and in neonatal mice (Niessen et al., 2011) , others demonstrating an inhibitory role in adult mice . While these discrepancies could be explained by age-and/or species-dependent differences, another complication is that Notch signalling occurs through different mechanisms. Notch signalling can proceed via the canonical pathway -involving nuclear translocation of the cleaved Notch receptor and binding to RBPJk -or independent of it (Sanalkumar et al., 2010) . The (relative) importance of both pathways in LECs, however, remains a matter of debate (Geudens et al., 2010; Srinivasan et al., 2010) .
One potential mechanism by which a common transcription factor may acquire EC subtype-specific regulatory properties is by its (physical) association with another transcription factor that is uniquely expressed in one of the EC subtypes. Recently, two labs independently demonstrated that NR2F2 forms functional heterodimers with the LEC-restricted transcription factor PROX1 in LECs (Lee et al., 2009; Yamazaki et al., 2009 ). Furthermore, both transcription factors were shown to drive the expression of a LEC gene subset in a cooperative manner, while other genes were regulated independently by either factor alone (Lee et al., 2009) . However, these studies did not address whether heterodimerisation with PROX1 in LECs was responsible for a differential effect of NR2F2 on gene expression in LECs versus VECs.
Here, using a combination of loss-and gain-of-function studies in human ECs, we unravel a novel mechanism whereby NR2F2 differentially regulates transcription of Notch target genes HEY1 and HEY2 (HEY1/2), in VECs and LECs by directly acting on their promoters. This interaction resulted in a transcriptional block on HEY expression in VECs, but not in LECs. We further show that NR2F2 switched from forming homodimers in VECs to heterodimerisation with PROX1 in LECs, the latter resulting in the release of the transcriptional block on HEY expression. HEY expression in LECs was at least partly independent of canonical Notch signalling. Moreover, the homo-heterodimerisation switch was responsible for the differential regulation by NR2F2 of a major subset of LEC and VEC genes.
Results

NR2F2 directs distinct transcriptional/functional programs in VECs and LECs
As shown here (Fig. 1A,B) and previously by others, while PROX1 expression is restricted to LECs, NR2F2 is commonly expressed in VECs (You et al., 2005) and LECs during development (Lin et al., 2010; Srinivasan et al., 2010) and adulthood (Lee et al., 2009; Lin et al., 2010; Yamazaki et al., 2009) , raising the question how one transcription factor can regulate and/or maintain both EC identities. To globally understand differential gene regulation, we performed a genome-wide comparative transcriptome analysis of human umbilical vein ECs (HUVECs) and a homogenous LEC population in the presence or absence of NR2F2. Despite a similar knockdown efficiency (,80% at RNA level) in both EC types, NR2F2 knockdown in HUVECs and LECs revealed remarkably different changes in their gene expression profile. Up to 204 genes were exclusively regulated by NR2F2 knockdown in HUVECs (e.g. HEY1/2), 191 were exclusively regulated in LECs (e.g. LYVE1, ITG9A), while only 54 genes were commonly regulated in both cell types (e.g. NRP2; Fig. 1C ; a complete list of genes significantly affected by NR2F2 knockdown is provided in supplementary material Table S1 ). Ingenuity Pathway Analysis revealed that genes that were differentially affected by NR2F2 knockdown belonged to distinct pathways (Fig. 1C) . Functional annotation analysis identified molecular transport as the most abundant function regulated by NR2F2 in HUVECs, whereas cellular movement was the primary function in LECs (Fig. 1D ). In accordance with published data (Lin et al., 2010) , cultured LECs migrated less in the absence of NR2F2 in response to VEGF-C (Fig. 1D) . Thus, NR2F2 orchestrates distinct transcriptional and functional programs in VECs and LECs.
NR2F2 differently affects HEY expression in VECs and LECs
The principal pathway differentially affected by NR2F2 knockdown was the Notch pathway. In endothelial-specific NR2F2-deficient mice, Notch pathway members become ectopically expressed in VECs. This generated a working model whereby NR2F2 regulates VEC identity by blocking the arterial VEGF-Notch cascade; however, how NR2F2 blocks Notch signalling in VECs was not directly tested (You et al., 2005) . Consistent with a repressive effect of NR2F2 on Notch signalling, NR2F2 knockdown in HUVECs resulted in a significant upregulation of NOTCH4, delta-like (DLL)4, HEY1 and HEY2 (Fig. 1E ). This was accompanied by an arterio-venous expression shift with increased expression of arterial transcript EFNB2 and lowered expression of venous transcripts, EPHB4 and NRP2 (Fig. 1E) . Remarkably, in LECs, none of the Notch pathway members was affected by NR2F2 silencing, nor was the expression of EFNB2 (Fig. 1F) . Thus, while NR2F2 inhibited expression of Notch pathway members in HUVECs, this did not occur in LECs resulting in a significantly higher expression of Notch targets HEY1/2 in untreated LECs versus HUVECs (Fig. 1G-K) .
NR2F2 binding to HEY promoters blocks their expression in HUVECs but not in LECs
We next assessed how differential gene regulation by NR2F2 in EC subtypes was accomplished, first focusing on the Notch pathway. Since our data suggested a direct repressive effect on HEY1/2 expression in HUVECs, we investigated whether NR2F2 could bind to their promoters to block HEY1/2 transcription. For both promoters we identified four regions each containing an evolutionary conserved putative NR2F2 binding element ( Fig. 2A,B) . Chromatin immunoprecipitation revealed a true NR2F2 binding site in the proximity of the transcriptional start site of both genes (corresponding to a direct repeat (DR)4 element in intron 1 of the human HEY1 promoter and an inverted repeat (IR)1 element upstream of the 59 untranslated region (UTR) in the human HEY2 promoter; Fig. 2C,D) in HUVECs. Mutation of these sites (to prevent NR2F2 DNA binding) resulted in increased HEY1/2 promoter activity (Fig. 2E) , proving that NR2F2 blocks Notch signalling in HUVECs at least partly by direct interaction with these HEY1/2 promoter elements causing transcriptional repression. However, NR2F2 bound the same sites of both genes in LECs (Fig. 2C,D) , suggesting that the observed lack of inhibition of Notch targets in LECs was not due to NR2F2's inability to bind the corresponding NR2F2 sites. Of note, NR2F2 binding to the HEY2 promoter was less prominent in LECs (Fig. 2D) . Hence, reduced binding to the HEY2 promoter could partly account for the lack of HEY2 repression in LECs. Thus, while NR2F2 inhibits arterial gene expression in veins through binding to the promoters of HEY1/2 causing their repression, such interactions in LECs are less efficient and/or do not induce transcriptional repression.
HEY expression in LECs is at least in part independent of canonical Notch signalling
Since the role of canonical Notch signalling in LECs has been debated (Geudens et al., 2010; Srinivasan et al., 2010) , we wondered whether basal Notch target gene expression was either the result of canonical regulation (involving generation of Notch intracellular domain or NICD by Notch receptor cleavage and subsequent association with RBPJk to form a transcriptional regulatory complex), or rather NICD/RBPJk-independent. In support of the latter hypothesis, RBPJk siRNA knockdown or treatment with DAPT {N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; a Notch receptor cleavage inhibitor} did not change HEY1/2 expression in LECs (Fig. 2F,G) . Thus, NICD/RBPJk-independent regulation is likely involved in basal Notch target gene expression in cultured LECs.
NR2F2 forms homodimers in HUVECs but heterodimerises with PROX1 in LECs
As differential DNA binding efficiency did not entirely explain NR2F2's divergent effect on HEY repression in HUVECs and LECs, we hypothesised that the inability of NR2F2 to repress HEY in LECs is related to its association with PROX1, as such an association was recently shown (Lee et al., 2009; Yamazaki et al., 2009) (Fig. 3A) . Previous studies in non-ECs demonstrated that NR2F2 forms stable homodimers and that each monomer binds to one half-site of the NR2F2 binding element (Cooney et al., 1992; Pereira et al., 2000) . Using a proximity ligation assay (PLA), we demonstrated that NR2F2 also associates with itself in HUVEC nuclei ( Fig. 3B-D) . In contrast, NR2F2 homodimers were nearly undetectable in LEC nuclei, but numerous NR2F2/PROX1 heterodimers were present there (Fig. 3C ,F,G). NR2F2/PROX1 heterodimeric complex formation at the HEY promoters was further suggested by the observation that PROX1 binding occurred at the same sites as NR2F2 in LECs (Fig. 2C,D) . Interestingly, NR2F2 homodimers were predominantly located in the cytoplasm rather than the nucleus, while only few NR2F2/ PROX1 heterodimers were found in the cytoplasm in LECs (Fig. 3C ,F,G). Thus, the unique expression of PROX1 caused a switch from NR2F2 homo-to heterodimerisation in LEC nuclei.
NR2F2 homo-and heterodimers differentially regulate gene expression in HUVECs and LECs
We next tested whether the switch from NR2F2 homodimerisation in HUVECs to heterodimerisation with PROX1 in LECs was responsible for the inability of NR2F2 to repress HEY genes and its ability to activate LEC-specific genes. We therefore modified the NR2F2/PROX1 expression balance by siRNA knockdown or lentiviral overexpression of PROX1. PLA showed that our manipulations yielded the intended shifts in the homo-/ heterodimer balance ( Fig. 4A -E,G-K). When PROX1 was overexpressed in HUVECs to promote heterodimerisation (and mimic the situation in LECs), expression of HEY1/2 was increased ( Fig. 4F ) in addition to several others of the 125 'type A' genes that are -like HEY1/2 -normally inhibited by NR2F2 in HUVECs but not in LECs (Fig. 5A,B) . By contrast, PROX1 knockdown in LECs to favour NR2F2 homodimerisation (like in HUVECs) inhibited expression of a sampled subset of these genes (including HEY1 but not HEY2; Fig. 4L ; Fig. 5A,C) . Consistent with the ability of NR2F2 to activate gene expression when forming heterodimers with PROX1, overexpression of the latter in HUVECs activated the expression of a sampled subset of the 105 'type B' LEC marker genes induced by NR2F2 in LECs only (Fig. 5A,D) . Conversely, PROX1 knockdown inhibited the expression of these genes (Fig. 5A,E ).
Direct interference with heterodimer formation further supports its major role in differential gene expression
In order to complement these homo-heterodimer shifts, we performed experiments to more directly interfere with NR2F2/ PROX1 heterodimer formation. Therefore, we mutated the nuclear receptor (NR) domains in the PROX1 N-terminus (Fig. 6A ), previously suggested (Lee et al., 2009; Srinivasan et al., 2010 ) -but not shown -to be responsible for interaction with nuclear receptors, including NR2F2, while not affecting PROX1's inductive capacity for LEC gene expression ). While we confirmed that this PROX1 mutant retains its activity to induce LEC genes, including PDPN, FLT4 and REELIN (RELN; Fig. 6B ), the NR mutations did not abrogate heterodimerisation with NR2F2 upon overexpression in HUVECs ( Fig. 6C-E) . Accordingly, these mutations did not impair PROX1's ability to boost HEY expression (Fig. 6B) . Since the PROX1 NR mutant was not an appropriate tool to directly affect heterodimerisation, we used an alternative approach, i.e. simultaneous overexpression of PROX1 and knockdown of NR2F2 in HUVECs, the latter to disrupt NR2F2/PROX1 heterodimers resulting from PROX1 overexpression (Fig. 7 , scheme on the left). In support of a major role for homoversus heterodimerisation in the differential regulation of gene expression by NR2F2, for five out of six sampled 'type B' genes, heterodimer disruption abolished the expression boost induced by PROX1 overexpression (Fig. 7 , bar diagrams on the right).
PROX1 DNA binding is required for inducing expression of an NR2F2-regulated LEC gene subset Finally, we explored whether the formed NR2F2/PROX1 heterodimers were either permissive for or rather actively inducing the expression of 'type A' genes, the latter through binding of PROX1 to DNA. To test this, we overexpressed a PROX1 DNA binding-deficient mutant in HUVECs, which did not interfere with heterodimerisation ( Fig. 8A-D) . Expression of a subset of 'type A' genes, including HEY1, was dependent on PROX1 DNA binding for its induction, while for others, including HEY2, PROX1 DNA binding was not required (Fig. 8E, left) . Similarly, for 'type B' genes, the expression boost by NR2F2/PROX1 heterodimerisation may be additionally dependent on binding of PROX1 to regulatory sequences in their DNA. Indeed, in a set of six sampled 'type B' genes, four out of six were significantly dependent on PROX1 DNA binding (Fig. 8E, right) . Thus, PROX1 DNA binding-dependency superimposed another level of regulation on NR2F2/PROX1 heterodimerisation for gene expression in LECs. Discussion AEC, VEC and LEC identities are in part genetically predetermined. NR2F2 orchestrates arterio-venous and venolymphatic decisions during development, a role that is evolutionary conserved across vertebrates (Aranguren et al., 2011; Lee et al., 2009; Lin et al., 2010; Srinivasan et al., 2010; You et al., 2005) . Here, we demonstrated a differential effect of NR2F2 on gene and functional regulation in VECs and LECs. We propose a model whereby homo-versus heterodimerisation with PROX1 majorly determines this differential regulation. In VECs, NR2F2 homodimers blocked arterial differentiation by directly repressing HEY genes through binding to their promoters. In LECs, NR2F2/PROX1 heterodimers did not block HEY expression and induced a complement of LEC signature genes. HEY expression in LECs was at least partly independent of canonical Notch signalling. Furthermore, for some genes, expression in LECs was additionally dependent on PROX1 DNA binding.
Our first principal finding was that NR2F2, commonly expressed in VECs and LECs, drives strikingly different genetic and functional programs in these EC subtypes. Transcriptome analysis revealed that of the 449 genes significantly affected by NR2F2 knockdown in HUVECs and/or LECs, 88% of these were differently regulated by NR2F2 between HUVECs and LECs. Among the 'type A' genes specifically upregulated by NR2F2 knockdown -thus transcriptionally blocked by NR2F2 -in HUVECs were Notch target genes HEY1/2, consistent with the previously published hypothesis that NR2F2 blocks Notch signalling in VECs (You et al., 2005) . While according to that hypothesis NR2F2 blocked Notch in VECs by acting at the level of VEGF co-receptor Nrp1 (You et al., 2005) , our studies revealed an alternative mechanism of directly blocking Notch target genes, i.e. by binding of NR2F2 to DNA binding elements in their promoter. Chen et al. recently reported an additional transcriptional repressive NR2F2 DR3 binding element in the HEY2 promoter in close vicinity to the IR1 binding element identified in our screen, suggesting that NR2F2-mediated HEY2 repression in Proximity ligation assays (PLA) reveal that this manipulation results in a reduction of NR2F2 homodimers (dots in B-E; schematically shown as yellow ellipses in A,F) in the nucleus (Nucl; stained with Topro in blue) and -to a lesser extent -in the cytoplasm (Cyto; B,C) and a gain of NR2F2/PROX1 heterodimers (D,E; schematically shown as yellow/magenta ellipses) in the nucleus of HUVECs, resembling the situation in LECs. The corresponding quantification is shown in A (data represent mean number6s.e.m.; *P,0.05, **P,0.01 versus lentiGFP). The nuclear homo/heterodimer ratio (Ho/He) is significantly reduced in PROX1-overexpressing HUVECs (A). As a result of this shift, the blocking effect of NR2F2 homodimers on HEY1/2 expression is released (F: data represent mean percentage6s.e.m. versus lentiGFP; N56 independent experiments; *P,0.05 versus lentiGFP). (G-L) PROX1 knockdown in LECs. PLA reveals that this manipulation causes a gain of homodimers in the nucleus and the cytoplasm (H,I) and a loss of NR2F2/PROX1 heterodimers in the nucleus (J,K) of LECs, resembling the situation in HUVECs. The corresponding quantification is shown in G [data represent mean number6s.e.m.; **P,0.01 versus non-silencing (siNS) siRNA]. The nuclear homo/heterodimer ratio (Ho/He) is significantly increased in PROX1-depleted LECs (G). As a result of this shift, the transcriptional block on HEY1 -but not on HEY2 -expression is restored (L: data represent mean percentage6s.e.m. versus siNS; N54 independent experiments; *P,0.05 versus siNS). For clarity, expected expression changes for each of the manipulations is schematically shown at the top of F and L. Scale bars: 10 mm.
VECs requires interaction with multiple promoter binding sites (Chen et al., 2012) . In contrast, even though NR2F2 also associated with the promoters of HEY1/2 in LECs, the latter were not transcriptionally repressed by NR2F2 in these cells. As a consequence, HEY1/2 expression was more than 10-fold higher in LECs compared with HUVECs. Furthermore, this also means that HEY1/2 and NR2F2 were co-expressed in LECs, unlike in AECs where NR2F2 expression in AECs is absent due to Notch activity involving HEY1/2 (Kang et al., 2010; Sörensen et al., 2009) . We hypothesise that this may be explained by a dosage effect, whereby high HEY levels in AECs cause NR2F2 repression while lower basal levels in LECs do not. This dose dependency of HEY expression likely requires tight regulation.
How then is HEY expression differently regulated between AECs and LECs? The strikingly similar defects in AEC specification between mice deficient for Notch receptors/ ligands, Rbpjk and Hey1/2 indicate that in AECs, expression of Hey1/2 is the result of canonical Notch activation, requiring interaction of Rbpjk with the cleaved and nuclear translocated Notch receptor (Fischer et al., 2004; Krebs et al., 2004) . We found for the first time that basal HEY1/2 expression in cultured LECs is established at least in part independent of Notch cleavage or RBPJk. This is compatible with recent in vivo data failing to demonstrate canonical Notch activity in LEC (precursors) in zebrafish embryos (Geudens et al., 2010) and with the observation that lymphatic specification is independent of Rbpjk in mice and the not significantly affected HEY1 expression in LECs upon treatment with DAPT, a Notch cleavage blocker (Kang et al., 2010) . NICD/ RBPJk independent regulation of HEY genes has been suggested to play a role in non-endothelial cell types (Sanalkumar et al., 2010) and in blood vascular ECs. Indeed, Hey2 expression is not altered in the endocardium of Rbpjk mutant mice (Timmerman et al., 2004) . Moreover, VEGF-C binding to VEGFR3-expressing blood vascular ECs causes upregulation of HEY1/2 expression in the presence of Dll4-Fc -a Notch inhibitor preventing cleavage and nuclear translocation of the Notch receptor . While a similar Notch cleavage-independent/VEGF-Cinduced cascade may occur in VEGFR3-expressing LECs, another recent study showed that blocking Notch signalling (using the same Notch inhibitor) affected LEC sprouting, suggesting that canonical Notch signalling may also be active in LECs under certain conditions . Nevertheless, the potentially context-dependent role of Data reveal that the majority of genes showed significant changes that are expected based on the homo/heterodimer shift hypothesis. Data expressed as percentages versus the corresponding baseline control (lentiGFP for PROX1 overexpression and non-silencing siRNA for PROX1 siRNA knockdown) in B-E represent the mean6s.e.m. of 4-6 independent experiments (*P,0.05; **P,0.01; #P50.053).
canonical Notch signalling in LECs remains to be further elucidated (Geudens et al., 2010; Niessen et al., 2011; Srinivasan et al., 2010; Zheng et al., 2011) . Recent studies demonstrated that BMP-9/Alk1 signalling induces HEY gene expression in ECs (Larrivée et al., 2012; Morikawa et al., 2011) . Accordingly, our own (unpublished) findings suggest that HEY1/ 2 expression can be induced through BMP-9 signalling in LECs. Furthermore, Foxc1 and Foxc2 can activate HEY2 expression through direct binding of its promoter (Hayashi and Kume, 2008) . Whether non-canonical HEY2 induction in LECs is Foxcmediated remains to be determined.
Another novel mechanistic finding of our study was that NR2F2 differentially regulates VEC and LEC function and gene expression by switching from homodimerisation in VECs to heterodimerisation with PROX1 in LECs. While NR2F2/PROX1 heterodimer formation has been previously demonstrated in LECs (Lee et al., 2009; Yamazaki et al., 2009) , the consequences of this on the functional and transcriptional level have not been systematically analysed nor has there been a comparison with the role of NR2F2 (homodimers) in VECs. We used PLA in combination with overexpression or knockdown of PROX1 to demonstrate that the homo-heterodimer switch caused a striking difference in transcriptional regulation by NR2F2 in these EC subtypes. Unlike previous co-immunoprecipitation assays on cell lysates, PLA studies allowed us to evaluate the subcellular localisation of the interactions between individual NR2F2 and According to the current hypothesis, two elements in the N-terminal region of PROX1 (NR1 corresponding to LRKLL and NR2 corresponding to ISQLL) are involved in binding to LLLRLP in the C-terminus of NR2F2. Mutations (in red font) were performed in both NR elements, replacing (iso)leucine with alanine, as described by Srinivasan et al. . (B) Bar diagram representing the percentage expression6s.e.m. relative to lentiGFP in HUVECs treated with lentiGFP (white), lentiPROX1 (grey) or lentiPROX1NR mut (black). Consistent with the comparable heterodimerisation capacity of the NR mutated and the wild-type PROX1, the NR mutations did not abrogate the heterodimerisation-induced increase in expression of HEY1/2 and LEC signature genes (podoplanin or PDPN, VEGFR3 or FLT4 and reelin or RELN). *P,0.05 versus lentiGFP; N53 independent experiments; ns, not significant. (C-E) Proximity ligation assays revealing that the mutated PROX1 (PROX1NR mut ; E) was as efficient in forming heterodimers with NR2F2 as its wild type counterpart (D) upon overexpression in HUVECs. HUVECs transduced with lentiGFP (C) were used as a negative control. Scale bars: 10 mm. Fig. 7 . Disruption of NR2F2/PROX1 heterodimers abrogates PROX1-induced induction of 'type B' genes. The left diagram schematically shows the expected expression changes for 'type B' genes upon PROX1 overexpression in HUVECs (to mimic the situation in LECs) and upon disruption of NR2F2/PROX1 heterodimers by NR2F2 siRNA knockdown. The qRT-PCR bar diagram on the right represents the percentage expression6s.e.m. relative to lentiGFP+siNS (nonsilencing siRNA) in HUVECs treated with lentiGFP+siNS (white), lentiPROX1+siNS (grey) or lentiPROX1+siNR2F2 (black), revealing that expression of the majority of randomly sampled 'type B' genes was dependent on heterodimerisation. *P,0.05 versus lentiGFP+siNS or lentiPROX1+siNS; N57 independent experiments; # P50.11 versus lentiPROX1+siNS; $ P50.13 versus lentiPROX1+siNS; ns, not significant. PROX1 molecules. Interestingly, NR2F2 homodimers were found both in HUVECs and LECs; however, in LECs these homodimers were less abundant and mainly resided in the cytoplasm. NR2F2/PROX1 heterodimers on the other hand were located almost exclusively in the LEC nuclei. The preferential presence of NR2F2 homodimers in the LEC cytoplasm may be explained by several mechanisms, including trapping by another protein, the existence of active shuttling between the nuclear and cytosolic compartments, or the fact that the observed homodimers are in transition to the nucleus where they switch to heterodimer formation. A limitation of our study was that we could not confirm by mutations that disrupt the interaction between NR2F2 and PROX1 that the homo-heterodimerisation switch was responsible for the differential gene regulation in VECs versus LECs. This was due to the fact that the sequences in the PROX1 N-terminus implicated in heterodimerisation with nuclear receptors were not solely responsible for functional interaction of PROX1 with NR2F2 -as was demonstrated for its interaction with ERRa, another nuclear receptor (Charest-Marcotte et al., 2010) . Indeed, mutation of these sequences did not abolish NR2F2/PROX1 heterodimerisation nor did it affect HEY1/2 gene or LEC signature gene expression in established LECs. Notably, such mutations, however, did severely affect mouse lymphatic development Srinivasan and Oliver, 2011) . Future studies to identify protein residues involved in functional dimerisation of PROX1 with nuclear receptors are warranted. Because of this limitation, we used an alternative strategy to directly interfere with NR2F2/PROX1 heterodimerisation by combining PROX1 overexpression with NR2F2 knockdown. This allowed us to demonstrate that homoversus heterodimerisation was a major contributor to the differential gene expression programs driven by NR2F2 in VECs versus LECs.
Finally, we observed that for a subset of 'type A' genes, PROX1's role was not merely to form a heterodimer with NR2F2 and thereby be permissive for their expression but rather to actively induce it by binding to regulatory DNA sequences somewhere in the gene. Thus, PROX1 DNA binding added another level of complexity on top of the heterodimerisation shift for gene expression regulation in LECs. Taking together the two sets of experiments where we either knocked down PROX1 in LECs or overexpressed a DNA binding-deficient mutant of PROX1 in HUVECs, we could distinguish at least three potential regulatory scenarios. For some genes, including HEY1, the NR2F2/PROX1 heterodimer was actively inducing their expression and this involved PROX1 DNA binding. For these genes, disrupting the heterodimer by PROX1 knockdown or interfering with the DNA binding capacity of PROX1 by overexpression of the mutant affected their expression. For others, like TRPV2, the shift to a heterodimer conformation was permissive and sufficient for their expression in LECs. For this gene category, the expression was affected by disruption of the heterodimer but not by interfering with PROX1 DNA binding. For yet another subset, including HEY2, the expression was neither affected by disruption of the heterodimer nor by interfering with PROX1 DNA binding. We postulate that for those genes the NR2F2/PROX1 heterodimer is permissive but their expression is additionally dependent on a trigger that does not involve PROX1. It will be interesting to identify this additional trigger for HEY2, which also should be independent of canonical Notch signalling, as its expression was not affected by inhibiting this pathway. Similarly to 'type A' genes, also for 'type B' genes the expression in LECs of a subset of them was dependent on PROX1-DNA interaction. The latter happened in the context of the NR2F2/PROX1 heterodimer, as PROX1 overexpression was no longer able to induce the expression of those genes when combined with NR2F2 knockdown. Thus, gene expression regulation by NR2F2 and PROX1 is a multi-level and complex process.
In summary, here we identified a novel mechanism by which a commonly expressed transcription factor, NR2F2, differentially regulated venous and lymphatic gene expression and function in VECs and LECs by homo-versus heterodimerisation with the 
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LEC-specific transcription factor PROX1, respectively. Most intriguingly, unlike in VECs, NR2F2 did not block HEY1/2 expression in LECs and we demonstrated for the first time that their expression in LECs was at least in part independent of canonical Notch signalling. Furthermore, the expression of HEY genes as well as some others was dependent on an additional trigger in which PROX1 DNA binding was involved for a subset of these genes. Future studies will have to reveal the functional significance of these genes in LECs, most notably HEY genes, which were previously thought to be exclusively associated with arterial specification and function (Fischer et al., 2004; Gessler et al., 2002) .
Materials and Methods
Cell derivation, culture, immunostaining, FACS and functional assays HUVECs were obtained as described previously (Hendrickx et al., 2010) . HUVEC isolation was performed at the Clinica Universidad de Navarra according to the institutional guidelines and after obtaining informed consent. Human lung LECs were purchased from Lonza (Merelbeke, Belgium), cultured in EBM-2 supplemented with EGM-2-MV bullet kit and subjected to a quality control [including FACS for Podoplanin, western blotting for PROX1 and immunofluorescence (IF) staining for NR2F2, PROX1, Podoplanin and integrin9a], revealing that they were a homogenous population expressing NR2F2 (data not shown). The IF staining and FACS procedures were described earlier (Aranguren et al., 2007) and primary antibodies used were: mouse anti-human NR2F2 (Perseus Proteomics PPH714700; 1:50; Tokyo, Japan), rabbit anti-human/mouse Prox1 (Angiobio 11-002; 1:100; Del Mar, CA, USA), rabbit anti-human/mouse Lyve1 (Angiobio 11-034; 1:100), rabbit anti-human HEY1 (Santa Cruz (H120) SC28746; 1:20; Santa Cruz, CA, USA), rabbit anti-human HEY2 (Merck Millipore AB5716; 1:100; Overijse, Belgium), rabbit anti-human Podoplanin (Abcam ab 10274; 1:100; Cambridge, UK), and rabbit anti-human integrin9a (Santa Cruz SC68864; 1:20). All IF images were recorded on a Zeiss Axiovert 40CFL microscope equipped with a Zeiss MRm camera and Axiovision 4.5 software (Carl Zeiss, Zaventem, Belgium). The scratch wound migration assay was performed as described (Hendrickx et al., 2010) in the presence of 100 ng/ml recombinant human VEGF-C (R&D Systems, Abingdon, UK).
Knockdown, lentiviral overexpression and canonical Notch blockade in ECs siRNA knockdown was performed using SilencerH Select pre-designed siRNA from Applied Biosystems (Lennik, Belgium) for NR2F2 (siRNA ID#: s62513 and s14021); negative control 1 (siRNA ID#: am4636); PROX1 (siRNA ID#: s11229 and s11227) and RBPJk (siRNA ID#: s7251 and s7253). Briefly, 5000 cells in 1.9 cm 2 wells were plated on day 0 and transfected on day 1 with 5 pmol siRNA mixed with 0.5 ml of Lipofectamine 2000 (Life Technologies, Gent, Belgium) in 100 ml of OPTI-MEM (Life Technologies). The day after, transfection media was replaced and cells were maintained until day 3 or 6, the latter requiring an additional siRNA transfection round at day 3. In all cases negative control 1 siRNA-transfected cells were used as reference. Knockdown was verified by qRT-PCR and western blot. Lentiviral constructs for PROX1 overexpression and GFP control virus were from GeneCopoeia (Rockville, USA) and lentiviruses were produced as described (Consiglio et al., 2004) . Transduced cells were sorted (taking advantage of the IRES-GFP within the lentiviral constructs) into TRIzolH buffer 6 days later. For blocking Notch receptor cleavage, cells were treated with 60 mM DAPT (Calbiochem, San Diego, USA) or DMSO (control).
RNA isolation, qRT-PCR and western blotting
Total RNA from (sorted) cell lysates was extracted using TrizolH reagent or RLT lysis buffer (Qiagen, Venlo, The Netherlands). mRNA was reverse transcribed using Superscript III Reverse Transcriptase (Life Technologies) and cDNA underwent 40 amplification rounds on an ABI PRISM 7700 cycler (Perkin Elmer/ Applied Biosystems, Foster City, CA) as described (Hendrickx et al., 2010) . Primer sequences for qRT-PCR are listed in supplementary material Table S2 . mRNA levels were normalised using GAPDH as housekeeping gene. For western blotting, samples were collected in RIPA buffer (Sigma-Aldrich, Bornem, Belgium) and protein concentration was measured by the BCA assay. 40 mg of protein was used for blotting. Blot pictures were recorded with a Bio-Rad Chemidoc XRS+ molecular imager, equipped with Image Lab software (Bio-Rad Laboratories, Nazareth, Belgium). Antibodies used were: mouse anti-human NR2F2 (Perseus Proteomics PPH714700; 1:2000), rabbit anti-human/mouse PROX1 (Angiobio 11-002; 1:500), rabbit anti-human/mouse Lyve1 (Angiobio 11-034; 1:500) and mouse anti-human a-tubulin (Sigma-Aldrich T6199; 1:1000).
Microarray
HUVECs or LECs were treated with siRNA against NR2F2 or control siRNA (N54 for each condition) and total RNA was extracted in TrizolH 6 days after transfection. RNA quality and concentration were determined using Pico chips on a Bioanalyser 2100 (Agilent Technologies, Diegem, Belgium). Samples were processed in collaboration with the Nucleomics Core Facility for gene expression analysis using the Affymetrix HG-U133 Plus 2.0 GeneChip Oligonucleotide Microarray (Affymetrix, Santa Clara, CA). Per sample, an amount of 100 ng of total RNA spiked with bacterial RNA transcript positive controls (Affymetrix) was amplified and labelled using the GeneChip 39 IVT express kit (Affymetrix). All steps were carried out according to the manufacturer's protocol (Affymetrix). A mixture of purified and fragmented biotinylated aRNA and hybridisation controls (Affymetrix) was hybridised on Affymetrix HG U133 Plus 2.0 arrays followed by staining and washing in a GeneChipH fluidics station 450 (Affymetrix) according to the manufacturer's procedures. To assess raw probe signal intensities, chips were scanned using a GeneChipH scanner 3000 (Affymetrix). Functional analysis of the array data was done using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA).
Chromatin immunoprecipitation
ChIP was performed with the Transcription Factor Chromatin Immunoprecipitation Kit (Diagenode), according to the manufacturer's recommendations. Briefly, cells were harvested by trypsinisation, washed and fixed. Chromatin shearing was done in shearing buffer by sonication with a Bioruptor (Diagenode). The chromatin solution was clarified by centrifugation and an aliquot of 30 ml of sheared chromatin was put aside for preparation of input sample. The remaining 60 ml was immunoprecipitated using mouse monoclonal anti-NR2F2 antibody (Perseus Proteomics PPH714700; 8 mg), rabbit polyclonal anti-PROX1 antibody (Angiobio 11-002; 4 mg) or the corresponding isotype (Mouse IgG; Diagenode Kch819015; 8 mg; Rabbit IgG; Diagenode Kch903060; 4mg; Liège, Belgium). After reversing the cross-links, immunoprecipitated DNA fragments were extracted with phenol/chloroform/ isoamylalcohol, washed and dissolved in water. NHRscan (http://asp.ii.uib. no:8090/cgi-bin/NHR-scan/nhr_scan.cgi) and alibaba 2.1 software were used to screen for conserved NR2F2 binding elements. Primers for amplification of the immunoprecipitated DNA fragments were: HEY1, site 1: forward: 59AGCGCAG-GCCTGCCGCGGT39, reverse: 59CCTCCCCGCACTCAGACTT39; HEY1, site 2: forward: 59ATGATTCCGTTTTTGCCTCA39, reverse: 59CATTAAGCATAGT-GGTTTGGAAAA39; HEY2, site 1: forward: 59ATCTTCACCTCCCGGACTCT39, reverse: 59GTCAGCTCTGATGGTAGGAA39; HEY2, site 2: forward: 59TTGTT-GTTTGCTTCTTTTGGAT39, reverse: 59TCAAAAGCAGTTGGCACAAG39. Gel pictures were recorded with a Vilber Lourmat gel documentation system (Vilber Lourmat, Marne-la-Vallée, France).
Luciferase reporter assay and mutagenesis
Human HEY1 and HEY2 promoters were cloned from BAC into the pGL3 plasmid (Promega, Leiden, The Netherlands). NR2F2 binding elements in site 1 in proximity to the translational start ( Fig. 2A-D) were mutated using the QuikChange II XL Directed Mutagenesis Kit (Agilent Technologies, Diegem, Belgium). The DR4 element in the HEY1 promoter (59TGCCCTGCGCTGACCT39) was mutated to 59TaCaCTaCaCTaACtT39 and the IR1 element in the HEY2 promoter (59GCGTCATTGATCT39) was mutated to 59aCaTaATTaATCT39. For the luciferase assay, 40,000 HUVECs were plated the day before transfection in a 1.9 cm 2 well. Cells were co-transfected with Fugene HD (Roche, Vilvoorde, Belgium) using 450 ng of pGL3-HEY1 or pGL3-HEY2 plasmid and 50 ng TKRenilla. Twenty-four hours later, the luciferase/Renilla signal was measured using the Dual Luciferase Reporter Assay System (Promega) and a Microlumat LB96V Luminometer (Berthold Technologies, Vilvoorde, Belgium). Mutations in the PROX1 NR domains (Fig. 6A ) and the PROX1 DNA-binding domain (Fig. 8A ) were achieved as previously described (Shin et al., 2006; Srinivasan et al., 2010) using the above-mentioned mutagenesis kit.
Proximity ligation assays
In order to determine NR2F2 homodimerisation and/or heterodimerisation with PROX1, the Duolink II in situ Proximity Ligation Assay (Olink Bioscience, Uppsala, Sweden) was used. Briefly, to analyse NR2F2 homodimerisation 20 mg of monoclonal NR2F2 antibody (Perseus Proteomics PHH714700) was labelled with Duolink Probe marker PLUS (positive oligonucleotide) and another 20 mg with Duolink Probe marker MINUS (negative complementary oligonucleotide). To detect NR2F2/PROX1 heterodimers monoclonal mouse antibody against NR2F2 (Perseus Proteomics PHH714700) and polyclonal rabbit antibody against PROX1 (Angiobio 11-002) were used followed by Duolink II anti-mouse PLUS (positive oligonucleotide) and Duolink II anti-rabbit MINUS (negative complementary oligonucleotide) secondary antibodies. Corresponding IgGs were used as negative control (mouse IgG, Reliatech IgG-001, Wolfenbüttel, Germany; rabbit IgG, Sigma-Aldrich I5006). For both homodimers and heterodimers Duolink II Detection Reagent Orange was used to visualise protein interactions. The total number of signal dots was counted separately in the nucleus and the cytoplasm on confocal images recorded with a Zeiss LSM510 confocal microscope equipped with LSM510 software (Carl Zeiss).
Statistical analysis
Data, expressed as mean6s.e.m. comparing two groups, were analysed by Student's t-test. SPSS software was used for statistical analyses and differences were considered significant when P,0.05. Statistical analysis of the microarray data was performed in the R programming environment, in conjunction with the packages developed within the Bioconductor project (http://www.bioconductor.org). The analysis was based on the RMA expression levels of the probe sets that had at least once a present MAS 5.0 detection call. Differential expression was assessed via the moderated t-statistic, taking into account that the data was paired. To control the false discovery rate, multiple testing correction was performed and probes with a corrected P-value below 0.05 and |log2siCOUP2log2NS| .1 were selected.
